Merck reports another failure for Keytruda-Lynparza combo in non-small cell lung cancer
Merck has once again failed to boost the effects of its PD-1 blockbuster Keytruda by adding AstraZeneca’s PARP inhibitor Lynparza.
When given as a maintenance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
